Education
About Us
Working with TipRanks
Follow Us
PSIL - ETF AI Analysis
Top Page
AdvisorShares Psychedelics ETF (PSIL)
Rating:48Neutral
Price Target:―
Positive Factors
Improving Year-to-Date Performance
The ETF has delivered slightly positive returns so far this year, showing some recovery despite recent short-term weakness.
Several Strong-Performing Holdings
Key positions like Definium Therapeutics, GH Research, Alkermes, and COMPASS Pathways have shown strong or steady gains this year, helping support the fund’s overall results.
Focused Exposure to Psychedelic-Related Health Care
With most assets in health care companies tied to psychedelics and neurology, the fund offers targeted access to a specialized growth theme that is hard to replicate with broader ETFs.
Negative Factors
High Expense Ratio
The fund’s fee is relatively high for an ETF, which can eat into long-term returns compared with lower-cost alternatives.
Concentrated Sector and Thematic Risk
With nearly all assets in health care and focused on psychedelics-related companies, the ETF is highly sensitive to setbacks in this niche area, such as regulatory or clinical trial disappointments.
Mixed Performance Among Top Holdings
Several major positions, including ATAI Life Sciences, Relmada Therapeutics, NRX Pharmaceuticals, and Neurocrine, have shown weak performance this year, which can drag on the fund’s overall results.
PSIL vs. SPDR S&P 500 ETF (SPY)
AUM19.58M
RegionGlobal
Expense Ratio1.00%
Beta0.96
IssuerAdvisorShares
Inception DateSep 15, 2021
Dividend Yield11.55%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume12,715
30 Day Avg. Volume17,690
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
52.92Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSIL Summary
The AdvisorShares Psychedelics ETF (PSIL) is a health care fund focused on companies developing psychedelic-based drugs and treatments, mainly in the U.S. It does not track a traditional index, but instead targets a niche theme: pharma, biotech, and life sciences firms working on new therapies for mental health issues like depression and PTSD. Well-known names in the fund include Neurocrine and Alkermes. Someone might invest for potential long-term growth in an emerging medical area and to add diversification. A key risk is that these early-stage biotech stocks can be very volatile and may drop sharply if drug trials or regulations disappoint.
How much will it cost me?The AdvisorShares Psychedelics ETF (PSIL) has an expense ratio of 0.99%, meaning you’ll pay $9.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise involved in selecting investments.
What would affect this ETF?The AdvisorShares Psychedelics ETF (PSIL) could benefit from increasing acceptance of psychedelics in mainstream medicine and growing investment in mental health treatments, particularly for conditions like depression and PTSD. However, regulatory hurdles, slow drug approval processes, and potential shifts in public perception or government policies could negatively impact the sector’s growth. Global exposure and reliance on innovative but early-stage companies may add both opportunities and risks for investors.
PSIL Top 10 Holdings
PSIL is a high-conviction bet on psychedelic drug development, with performance hinging on a handful of volatile biotech names. Compass Pathways and Definium Therapeutics have been rising on clinical momentum, helping to pull the fund forward, while Alkermes adds a steadier, more established biotech anchor. On the flip side, ATAI and Relmada have been lagging, acting like sandbags on the portfolio, and GH Research has been choppy. The fund is almost entirely health care–focused and globally diversified, but very concentrated in early-stage, high-risk names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Atai Beckley N.V. | 9.91% | $1.92M | $1.23B | 124.50% | 47 Neutral | |
| Definium Therapeutics | 9.40% | $1.82M | $1.76B | 158.56% | 40 Neutral | |
| COMPASS Pathways | 8.36% | $1.62M | $631.69M | 75.94% | 47 Neutral | |
| Relmada Therapeutics | 7.77% | $1.51M | $326.33M | 1455.94% | 41 Neutral | |
| GH Research | 6.76% | $1.31M | $988.13M | 51.71% | 45 Neutral | |
| Alkermes | 6.53% | $1.27M | $4.77B | -16.65% | 80 Outperform | |
| Alto Neuroscience, Inc. | 6.08% | $1.18M | $644.94M | 484.79% | 42 Neutral | |
| Neurocrine | 5.85% | $1.14M | $12.86B | 13.35% | 80 Outperform | |
| Supernus Pharmaceuticals | 5.40% | $1.05M | $3.10B | 67.98% | 55 Neutral | |
| Cybin | 5.18% | $1.01M | ― | ― | 37 Underperform |
PSIL Technical Analysis
Negative
―
Price Trends
17.12
Negative
17.19
Negative
15.93
Positive
Market Momentum
-0.05
Positive
41.64
Neutral
23.98
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSIL, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 16.91, equal to the 50-day MA of 17.12, and equal to the 200-day MA of 15.93, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 41.64 is Neutral, neither overbought nor oversold. The STOCH value of 23.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSIL.
PSIL Peer Comparison
Comparison Results
Performance Comparison
PSIL
AdvisorShares Psychedelics ETF
16.27
5.64
53.06%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents